Detailed Insights: LM-364 (“Nectin-4 TME ADC”)

• Innovative Mechanism: LM-364 utilizes LaNova’s proprietary tumor microenvironment (TME) platform, leveraging an adenine nucleotide (ANP)-dependent binding mechanism. This allows LM-364 to achieve conditionally activated, high-affinity binding at tumor sites, enhancing both internalization and payload release. Most importantly, this mechanism dramatically reduces off-target toxicity in normal tissues.
• Addressing Clinical Challenges: Nectin-4 is a validated target for various solid tumors (urothelial carcinoma, triple-negative breast cancer, cervical cancer, esophageal cancer). However, previous clinical development has been hampered by low-level Nectin-4 expression in normal tissues, leading to dose-limiting toxicities such as rash and neurotoxicity. LM-364’s approach directly addresses these safety concerns.
• Preclinical Efficacy:
  • Demonstrated precise targeting and potent cytotoxicity with efficient internalization and strong bystander effect.
  • Broad-spectrum antitumor activity in multiple patient-derived xenograft (PDX) models: Tumor Growth Inhibition (TGI) rates of 119.1% (triple-negative breast cancer), 107.46% (urothelial carcinoma), 168.79% (cervical cancer), and 86.73% (esophageal cancer).
• Safety Profile: Favorable tolerability observed in 7-week repeated-dose toxicity studies in SD rats and rhesus monkeys. Highest non-severely toxic dose (HNSTD) in rhesus monkeys was 60 mg/kg.
• Regulatory & Development Milestone: IND application filed with FDA, first-in-human clinical study targeted for 2026.

Detailed Insights: LM-338 (“STn ADC”)

• First-in-Class Potential: LM-338 targets Sialyl-Thomsen-nouveau (STn), a highly tumor-specific glycan antigen minimally expressed in normal tissues but elevated in a wide range of solid tumors (ovarian, breast, bladder, cervical, colorectal, pancreatic, NSCLC).
• ADC Construction: Humanized monoclonal antibody conjugated to a topoisomerase I inhibitor via a cleavable linker, with a drug-to-antibody ratio (DAR) of 4.
• Preclinical Efficacy:
  • High target specificity and internalization efficiency; minimal cross-reactivity to structural analogs.
  • Potent in vitro cytotoxicity and strong bystander effect.
  • In CDX and PDX mouse models (ovarian, colorectal, NSCLC), LM-338 monotherapy induced significant tumor growth inhibition and complete tumor regression.
• Safety Profile: Toxicology studies in rhesus monkeys showed HNSTD of 60 mg/kg with overall good tolerability.
• Clinical Implications: The robust preclinical data supports LM-338’s clinical development for STn-positive solid tumors.

Potential Impact for Investors and Shareholders

• Significant Advancements in Oncology Portfolio: The presentation of compelling preclinical data for two ADC programs underscores Sino Biopharmaceutical’s leadership in next-generation cancer therapeutics, potentially enhancing its competitive position and valuation.
• Regulatory Progress & Clinical Opportunity: Submission of IND for LM-364 to the FDA, with clinical trials imminent, marks a critical milestone that could accelerate the path to commercialization and generate substantial market interest.
• First-in-Class Status & Broad Market Potential: LM-338’s focus on the highly specific STn antigen targets a wide range of solid tumors, positioning it for broad clinical applicability and commercial opportunity.
• Improved Safety Profiles: Both candidates demonstrate favorable tolerability in animal studies, addressing longstanding safety concerns that have limited ADC adoption. This could increase market confidence and pricing power if these results are replicated in human trials.

Board and Management

• Sino Biopharmaceutical’s Board comprises six executive directors and five independent non-executive directors, with Ms. Tse, Theresa Y Y serving as Chairwoman. This leadership is expected to drive the company’s strategic direction through these pivotal development milestones.

Conclusion

The disclosure of highly promising preclinical data for LM-364 and LM-338—paired with imminent clinical development milestones and potential first-in-class status—constitutes a material event that could positively influence Sino Biopharmaceutical’s share price. Investors should closely monitor further updates as these programs advance toward clinical trials and potential commercialization.

Disclaimer: This article is based on information provided in the voluntary company announcement as of April 22, 2026. The content does not constitute investment advice. Investors are urged to undertake their own due diligence and consult with professional advisors before making investment decisions. Forward-looking statements may be subject to risks and uncertainties.

View SBP GROUP Historical chart here